The Massachusetts chapter of The Leukemia & Lymphoma Society (LLS) named Julian Adams, Ph.D., of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) as corporate chair of its 2014 Light The Night
Walk, LLS’s annual fundraising event for cancer research and patient services. Dr. Adams serves as president, research and development, at Infinity and is responsible for the full spectrum of the company’s drug discovery, preclinical and clinical development strategy and regulatory affairs activities.
LLS holds walks each fall in approximately 200 communities across the United States and Canada. Participants at the walks carry illuminated balloons – white for survivors, red for supporters, and gold to remember those who have died – to honor and commemorate lives touched by blood cancer.
“Forming Light The Night Walk teams is a great way to build team spirit among employees, raise awareness about the need for more blood cancer therapies and recognize those who continue to be affected by these diseases,” said Dr. Adams. “These same objectives – and our desire to continue our support of LLS – led us to recently launch Infinity Pharmaceuticals’ “
Sparks of Inspiration
” campaign. I am honored to serve as the chair of the 2014 Light The Night Walk and look forward to helping more local businesses and corporations get their employees involved.”
Prior to joining Infinity in 2003, Dr. Adams served as senior vice president, drug discovery and development at Millennium Pharmaceuticals. In this capacity, he held global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade
(bortezomib), a proteasome inhibitor for two different blood cancers: multiple myeloma and relapsed mantle cell lymphoma. He previously held senior management positions with organizations such as LeukoSite, ProScript, Inc. and Boehringer Ingelheim, where he successfully discovered the drug Viramune
(nevirapine) for HIV. Dr. Adams’ awards include the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade
from the International Myeloma Foundation.
The funds raised through corporate and individual contributions during the Light The Night
Walk help to find cures and better therapies for leukemia, lymphoma, Hodgkin disease and myeloma. Donations also provide information, education and support for patients and their families.
“Light The Night Walk gives hope to patients and their families and lets them know they are not alone in their battle against cancer,” said Sharon Klein, executive director of the Massachusetts chapter of the LLS.